Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response
Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response
复制标题
DOI：
10.1136/ard.2007.077461
复制
发表时间：
2008-07-01
影响因子：
27.4
通讯作者：
Elkayam, O.
中科院分区：
文献类型：
--
作者：
Oren, S.;Mandelboim, M.;Elkayam, O.
目的：评价利妥昔单抗对类风湿关节炎(RA)患者接种流感病毒疫苗的疗效和安全性的影响。使用裂解病毒灭活疫苗，其血凝素为15 mU/g/剂量B/Shanghai/361/02(SHAN)、A/New Caledoun/20/99(NC)(H1N1)和A/California/7/04(CAL)(H3N2)。在接种当天和4周后，通过关节压痛和肿胀的数量、晨僵持续时间和疼痛评估来评估疾病的活动性。对接受利妥昔单抗治疗的患者的CD19阳性细胞水平进行评估。检测了血凝抑制(HI)抗体，定义为接种后4周或血清转换后抗体水平无保护性的患者(
Objective: To assess the effect of rituximab on the efficacy and safety of influenza virus vaccine in patients with rheumatoid arthritis (RA).Methods: The study group comprised patients with RA treated with conventional disease-modifying drugs with or without rituximab. Split-virion inactivated vaccine containing 15 mu g haemagglutinin/dose of B/Shanghai/361/02 (SHAN), A/New Caledonian/20/99 (NC) (H1N1) and A/California/7/04 (CAL) (H3N2) was used. Disease activity was assessed by the number of tender and swollen joints, duration of morning stiffness and evaluation of pain on the day of vaccination and 4 weeks later. CD19-positive cell levels were assessed in rituximab-treated patients. Haemagglutination inhibition (HI) antibodies were tested and response was defined as a greater than fourfold rise 4 weeks after vaccination or seroconversion in patients with a non-protective baseline level of antibodies (